Clinical trial
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
NCT01302249 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
- Lead sponsor
- Aerie Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- December 31, 2011
- Enrollment
- 66 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.